Assessing clinical implementation of past standards for interpretation and reporting of sequence variants in cancer https://t.co/0rXbRZ3hMg https://t.co/5bYloRQHgo
Post- analytical considerations: essential elements of a report 📄 📌 Patient/clinical info 📌 Test background/methodology, results & interpretation, limitations 📌 References and recommendations https://t.co/aibYq6K9Pf 15/
@jansen_marnix @DNA_gyrase @DocPatM @vreelant @lexyadams16 @PanCAN @letswinpc True! Yesterday's VUS can be today's Tier 1/2. https://t.co/vey4WIvMkT
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
Standards and Guidelines for the Interpretation and Reporting of Seque... https://t.co/UqXQ9kzGwl
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey25DnH #camoldx
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
RT @JMDiagn: Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqc…
Thanks for sharing! The full guideline is available online FREE to all readers: https://t.co/6bPtTlb9jv https://t.co/bJDKqcinLG
RT @NicoleKuderer: A reference from early 2017 on interpreting & reporting Seq Var in Cancer: Already needs updates but still very valuable…
A reference from early 2017 on interpreting & reporting Seq Var in Cancer: Already needs updates but still very valuable & a classic resource to know 👇
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
. @ASCO @AMPath @Pathologists Standardize Interp & Reporting of Seq Var in Cancer [12/16/16] https://t.co/maVmHZQiSy #oncopath #camoldx https://t.co/Qejey1O2w9
A nice article about the need for standardized interpretation and reporting in clinical NGS applications. Thanks for sharing @MuinJKhoury in the #NGSguidelines2clinic Twitter chat https://t.co/CIihO3BK4m
RT @MuinJKhoury: Work in progress: Implementing @ASCO @AMPath @Pathologists guidelines in @JMDiagn for interpreting and reporting sequence…
RT @MuinJKhoury: Work in progress: Implementing @ASCO @AMPath @Pathologists guidelines in @JMDiagn for interpreting and reporting sequence…
Work in progress: Implementing @ASCO @AMPath @Pathologists guidelines in @JMDiagn for interpreting and reporting sequence variants in cancer. https://t.co/gtytlm6xip #NGSguidelines2clinic https://t.co/ldsf3m8lBo
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
Nikiforova: #ampeurope2018 For reporting: https://t.co/G22oEoj6GC Ex: 45yo F thyroid nodule, TERT and NRAS vars. See germline vars, illus complexity of interpret.
Nikiforova: #ampeurope2018 And a long process, 14-18 months. JMD Validation: https://t.co/siZw2tdgJn Reporting: https://t.co/G22oEoj6GC
https://t.co/GVvGISIP4M Standards and Guidelines for the Interpretation of Sequence Variants- useful methodology to understand pathogenicity of identified gene variants: benign to pathogenic.
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
RT @AMPath: ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence vari…
ICYMI: Joint AMP/ @ASCO/@Pathologists recommendations on standards and guidelines for interpreting and reporting sequence variants in #cancer, FREE in @JMDiagn: https://t.co/RFma8m23gK #worldcancerday
RT @JMDiagn: Read the full guideline for FREE here: https://t.co/oGSMQNxpm3 https://t.co/bZ5mh1ZTEf
Read the full guideline for FREE here: https://t.co/oGSMQNxpm3 https://t.co/bZ5mh1ZTEf
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
RT @JMDiagn: Available online FREE to all readers! #moldx #molpath https://t.co/gKhtiDHLBo
Available online FREE to all readers! #moldx #molpath https://t.co/gKhtiDHLBo
2017 Highlight: AMP issued new joint guidelines to standardize interpretation and reporting of sequence variants in #cancer: https://t.co/RFma8m23gK @ASCO @Pathologists #NGS #Molpath https://t.co/vhXDT6fzz8
2017 Highlight: AMP issued new joint guidelines to standardize interpretation and reporting of sequence variants in #cancer: https://t.co/RFma8m23gK @ASCO @Pathologists #NGS #Molpath https://t.co/7lj182qOXe
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
RT @n8pennell: Yes we have a similar molecular tumor board that makes evidence-based recs and recommends trials, but we’d be in trouble if…
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
Yes we have a similar molecular tumor board that makes evidence-based recs and recommends trials, but we’d be in trouble if number of cases jumped dramatically. Not sure this is tenable soln nationwide. https://t.co/dDC7F1PeJx
@n8pennell In our oncology #PrecisionMedicine program we classify explicitly by evidence level and prioritize clinical trials. Highlights need for systamtic structure and rigor. https://t.co/kYspTiPWQS
RT @DaleYuzuki: Li: Other rec's: clear desc of clin sig; clear desc of confirmation methods. Ref J Mol Diagn '17 https://t.co/Noyq5Y9Fzv #A…
RT @DaleYuzuki: Li: Other rec's: clear desc of clin sig; clear desc of confirmation methods. Ref J Mol Diagn '17 https://t.co/Noyq5Y9Fzv #A…
Li: Other rec's: clear desc of clin sig; clear desc of confirmation methods. Ref J Mol Diagn '17 https://t.co/Noyq5Y9Fzv #AMP2017
RT @JMDiagn: The full report is available from JMD and FREE to all readers: https://t.co/oGSMQNxpm3 #variants #cancersequencing https://t.…
RT @JMDiagn: The full report is available from JMD and FREE to all readers: https://t.co/oGSMQNxpm3 #variants #cancersequencing https://t.…
RT @JMDiagn: The full report is available from JMD and FREE to all readers: https://t.co/oGSMQNxpm3 #variants #cancersequencing https://t.…
The full report is available from JMD and FREE to all readers: https://t.co/oGSMQNxpm3 #variants #cancersequencing https://t.co/Cjv5I5zAsH
RT @WayneLiangMD: #CI4CC2017 https://t.co/lZWzUpwoEU @AMPath @ASCO @Pathologists joint #guidelines: categorization of #cancersequencing #v…
RT @WayneLiangMD: #CI4CC2017 https://t.co/lZWzUpwoEU @AMPath @ASCO @Pathologists joint #guidelines: categorization of #cancersequencing #v…
#CI4CC2017 https://t.co/lZWzUpwoEU @AMPath @ASCO @Pathologists joint #guidelines: categorization of #cancersequencing #variants https://t.co/VcpXvo21vT
RT @Dr_ZiMingZhao: Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer https://t.co/qokOnxcpD9
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer https://t.co/qokOnxcpD9
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li etal JMolDx https://t.co/Qejey25DnH #camoldx
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li etal JMolDx https://t.co/Qejey1…
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li etal JMolDx https://t.co/Qejey1…
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li etal JMolDx https://t.co/Qejey1…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li etal JMolDx https://t.co/Qejey1O2w9 #camoldx
RT @bioinformatics1: Reddy: Somatic variants in cancer standards for interpretation and reporting https://t.co/rUawpnbMmp #BioIT17
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey…
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9 #camoldx
2017 Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer https://t.co/MUs6m8eriJ
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. https://t.co/Qejey1O2w9 #camoldx
Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qejey1O2w9
Reddy: Somatic variants in cancer standards for interpretation and reporting https://t.co/rUawpnbMmp #BioIT17
RT @JMDiagn: Available in JMD here: https://t.co/oGSMQNxpm3 https://t.co/msHOqfzcgY
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…
RT @mtmdphd: Interp & Reporting Seq Var in Cancer: Consensus Rec @AMPath @ASCO @Pathologists [1/2017] Li et al. J Mol Dx https://t.co/Qe…